Our team

Anaïs is AmyPore’s project leader, in charge for its growth and operational development. She holds a Ph.D. from University of Montréal in Biochemistry and she was a researcher at Harvard Medical School and then at Centre de Recherche en Cancérologie de Marseille. Dr. Aulas applied her multiple competencies in Biochemistry, Neurosciences and Cancerology. Her international background in Canada, United-States of America and in France enables her to develop innovative research on the implication of cellular stress in major human pathologies. Dr. Aulas spent 13 years contributing to the neurosciences, cancer and stress fields, working in both fundamental and translational research.

Mohand Sidi Saïd is a former Vice-President of Pfizer Inc,. He is the President of an Endowment Fund, an author, and a lecturer, among others at Aix PO and ESSEC in Paris. He is a fervent defender of access to innovative care for the most disadvantaged in our societies. Mohand has authored numerous articles on health models, and he has published "The Spirit and the Molecule" in 2012, "Help, Our Health is in Danger", in 2016, "From Djurdjura to Manhattan", in 2020. Mohand Sidi Saïd is a passionate follower of the knowledge economy, AI and has a unique understanding of the life sciences industry. He joined the Amypore team in 2020 to participate in the development of the AmyP53 solution and contribute with insights and his network.

Professor at the University of Aix-Marseille, member of the Institut Universitaire de France, Jacques Fantini is the author of more than 200 scientific publications (including 4 PNAS articles communicated by two Nobel Prizes and two Lasker Prizes). A globally recognized specialist in molecular modeling, he has developed new concepts of artificial intelligence applied to membrane systems in the context of molecular neurosciences and infectious diseases. He is the co-inventor of the patented AmyP53 molecule for which he holds, with Pr. Nouara Yahi, the intellectual property.

Professor at the University of Aix-Marseille, Nouara Yahi is the author of more than 100 scientific publications (including 1 Nature and 2 PNAS communicated by a Nobel Prize and a Lasker Prize). Her work on the mechanisms of HIV infection is directly behind the discovery of the common mechanisms of amyloid pore formation and the role of membrane lipids (gangliosides and cholesterol) in this process. Prof. Nouara Yahi is co-inventor of the patented AmyP53 molecule, of which she, along with Prof. Jacques Fantini, holds the intellectual property.

Professor at Toulouse University Hospital, Jérémie Pariente (M.D., Ph.D.) is head of the service dedicated to cognitive disorders and abnormal movements within the Department of Neurology. Jérémie Pariente has been very involved in the Clinical Investigations Center of the Toulouse University Hospital for many years and has conducted several academic and industrial studies on Alzheimer's disease and related pathologies. Jérémie Pariente is a board member of the French Society of Neurology. He advises AmyPore on setting up clinical trials as part of the development of the AmyP53 program.

Dr. Di Scala obtained his doctoral thesis in 2014 on amyloid pores. She has internationally recognized skills in molecular neuroscience. She is currently leading a neuroscience research team in Helsinki, Finland.

A Master 2 Grande Ecole Program graduate from Kedge Business School and also from the University of Aix-Marseille entrepreneurship Pépite-PACA, Driss Fantini created the AmyPore Company in 2018, and was therefore responsible for the H2020 SME Phase 1 AmInnovation program.

After studying business and fashion, Mélodie Bricha worked in major luxury houses in Paris, London, Venice and New York. A social-concerned entrepreneur, she is also working on a digital project related to childhood. Mélodie also invests personally in various start-ups of international level.

Assistant Professor at the University of Aix-Marseille, Dr. Henri Chahinian is an internationally recognized specialist in the biochemistry of lipids and proteins of biological membranes. He has 40 years of experience in basic and applied research.